Amgen Launches First Humira (adalimumab) Biosimilar Amjevita in the US
Shots:
- The company has launched Amjevita (adalimumab), the first biosimilar referencing blockbuster drug Humira on the US market for certain serious inflammatory diseases. Amjevita will be available in a prefilled syringe & auto-injector pen
- Amjevita (40mg) is available with 2 pricing options. One pricing will be a 5% discount below the current list price of Humira while the other pricing will be a 55% discount. Multiple other adalimumab biosimilars are set to launch in the US in July 2023
- In Sept 2016, Amjevita was the first adalimumab biosimilar to be approved in the US & is also available in the EU & Canada. The company provides a patient support program i.e., AMJEVITA SupportPlus incl. financial support information & educational resources
Ref: Amgen | Image: Amgen
Related News:- Prime Therapeutics will Include Biosimilars to the NetResults Formulary in Addition to Humira
Click here to read the full press release
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
